黄芪总皂苷对大鼠缺血心肌血管内皮生长因子蛋白表达的影响  

The effect of Astragalus on VEGF in ischemic myocardium of rats

作　　者：于俊民[1] 张小波[1] 姜文[1] 王慧冬[1] 王凌云[1] 曹滨冬[1] 

机构地区：[1]哈尔滨医科大学附属第四医院老年病一病房,黑龙江哈尔滨150001

出　　处：《中国急救医学》2014年第11期1033-1035,共3页Chinese Journal of Critical Care Medicine

基　　金：黑龙江省教育厅科学技术研究项目（12521297）

摘　　要：目的探讨黄芪总皂苷对急性心肌梗死（AMI）大鼠缺血心肌组织血管内皮生长因子（VEGF）蛋白表达水平的影响。方法雄性Wistar大鼠24只，建立AMI模型，术后24h存活大鼠随机分为药物组（n＝8）、对照组（n＝8），另设假手术组（n＝8）。药物组给予黄芪总皂苷水溶液2．5mg/（kg·d）腹腔注射，对照组及假手术组给予等体积生理盐水，4周处死大鼠。心肌组织取材，Ⅷ因子染色计数微血管数（MVC）及微血管密度（MVD），免疫组化法观察缺血心肌VEGF蛋白表达水平。结果药物组及对照组大鼠缺血心肌MVC、MVD均高于假手术组，且药物组MVC、MVD高于对照组（P＜0．05）；药物组及对照组大鼠缺血心肌VEGF蛋白表达均高于假手术组（P＜0．01），且药物组高于对照组（P＜0．01）。结论黄芪总皂苷促进大鼠缺血心肌血管新生，同时可上调缺血心肌组织VEGF蛋白表达水平。Objective To study the effect of Astragalus on the level of vascular endothelial growth factor （ VEGF） in ischemic myocardium of rats.Methods The acute myocardial infarction （ AMI） models were established in twenty-four male Wistar rats.Twenty-four hours after procedure, the surviving rats were randomly divided into drug group （ n=8 ） , control group （ n=8 ） , and sham-operated group （n =8）.Rats in the drug group were injected with Astragalus [2.5 mg/（kg· d）] Intraperitoneally.The control group and the sham-operated group were received same volume saline intraperitoneally.Four weeks later, the rats were sacrificed and the myocardial tissue were collected. The number of miniature blood vessel （ MVC） and microvascular density （ MVD） was counted according to FⅧ staining technique, and the expression of VEGF was detected by immunohistochemistry technique.Results The number of MVC and MVD in drug group and control group was higher than that in sham-operated group, and the drug group was higher than the control group （P〈0.05）; higher expression of VEGF was shown in drug group and control group than sham-operated group （P〈0.01）, while the expression in drug group was higher than control group （P〈0.01）.Conclusion Astragalus can increase the level of VEGF and promote angiogenesis in ischemic myocardium of rats.

关 键 词：黄芪总皂苷 缺血心肌 血管内皮生长因子(VEGF) 

分 类 号：R-332[医药卫生]